Aggregated price index with volume information
Summary:
- Drugstore Chains stocks up 1.8% on average while median return up 1.7% in a day
- Drugstore Chains stocks down 3.3% on average while median return down -0.7% in a week
- Drugstore Chains stocks down 13.0% on average while median return down 10.4% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $YI 0.9%
- 1M losers are : Losers for past month are $PETS -14.7%, $CVS -24.4%
- 1W winners are : Winners for past week are $YI 12.7%, $PETS 0.7%
- 1W losers are : Losers for past week are $CVS -16.8%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 14.3%, for the past 3 months is 11.8%
In the past month for a 5 days rolling window, the highest corrrelation is 43.2%, the lowest correlation is -15.5%, the latest correlation is 32.7%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 38.6% between PETS and YI
The lowest correlation is -22.0% between BIMI and YI
Under the deal, Walgreens will find candidates who are overweight or have obesity or diabetes and connect them with a Phase III clinical trial for Boehringer’s GLP-1 drug survodutide.
Boehringer is collaborating with EmVenio Research to introduce mobile community research units to extend the reach of trials.
In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $17.53, indicating a +1.1% shift from the previous trading day.
Joint collaborations bring Boehringer Ingelheim's Phase III clinical trial to communities through Walgreens pharmacy clinical trial centers and EmVenio's mobile research units, aimed at improving access to trials Originally published by Walgreens ...
Walgreens is ramping up its clinical trial offerings with Big Pharma players.
Cigna Group raised its annual profit forecast on Thursday, helped by lower-than-expected medical costs and strength in its pharmacy benefit management unit. The health insurer's second forecast raise this year is in sharp contrast to some rivals that are struggling with increasing costs due to a much larger presence in the government-backed Medicare Advantage (MA) market for adults aged 65 and older. Cigna is in the process of exiting that business, with its $3.3 billion sale to Health Care Se...
Walgreens’ decision to slash VillageMD’s clinical footprint has reverberated to the financial accounts of the primary care chain’s minority owner — Cigna.
Walgreens Boots Alliance Inc. (NASDAQ:WBA) is facing tumultuous times as it grapples with a challenging turnaround, leading to a drastic decline in its stock value, marking its worst performance in over five years. The company’s shares plummeted by 18% in April, nearing a 26-year low, following a downward revision of its outlook. This revision was accompanied by concerns over decreased consumer spending and the revelation of a substantial unpaid tax liability amounting to $2.7 billion, adding to
Walgreens, Lumen, Truist and Verizon are among the companies with the largest impairments in the past year.
Q1 2024 Franklin BSP Realty Trust Inc Earnings Call